Takeda has filed for European approval of vedolizumab in inflammatory bowel disease, potentially providing new hope for spurned integrin inhibitors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Holmes, D. Integrin inhibitors go with the gut. Nat Rev Drug Discov 12, 411–412 (2013). https://doi.org/10.1038/nrd4037
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4037
This article is cited by
-
Vedolizumab: First Global Approval
Drugs (2014)